相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Radiofluorinated GPC3-Binding Peptides for PET Imaging of Hepatocellular Carcinoma
Youcai Li et al.
MOLECULAR IMAGING AND BIOLOGY (2020)
CUGC for Simpson-Golabi-Behmel syndrome (SGBS)
Marie-Laure Vuillaume et al.
EUROPEAN JOURNAL OF HUMAN GENETICS (2019)
Diffuse and canalicular patterns of glypican-3 expression reflect malignancy of hepatocellular carcinoma
Miho Kawaida et al.
PATHOLOGY INTERNATIONAL (2019)
Immunotherapeutic Targeting of GPC3 in Pediatric Solid Embryonal Tumors
Michael V. Ortiz et al.
FRONTIERS IN ONCOLOGY (2019)
A Frizzled-Like Cysteine-Rich Domain in Glypican-3 Mediates Wnt Binding and Regulates Hepatocellular Carcinoma Tumor Growth in Mice
Na Li et al.
HEPATOLOGY (2019)
Combined Antitumor Effects of Sorafenib and GPC3-CAR T Cells in Mouse Models of Hepatocellular Carcinoma
Xiuqi Wu et al.
MOLECULAR THERAPY (2019)
Glypican-3 promotes cell proliferation and tumorigenesis through up-regulation of β-catenin expression in lung squamous cell carcinoma
Dongchang Wang et al.
BIOSCIENCE REPORTS (2019)
Propofol-induced miR-219-5p inhibits growth and invasion of hepatocellular carcinoma through suppression of GPC3-mediated Wnt/β-catenin signalling activation
Ting Gong et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2019)
Performance of Serum Glypican 3 in Diagnosis of Hepatocellular Carcinoma: A meta-analysis
Dahai Xu et al.
ANNALS OF HEPATOLOGY (2019)
Long non-coding RNA FENDRR inhibits proliferation and invasion of hepatocellular carcinoma by down-regulating glypican-3 expression
Bian Wang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2019)
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Andrew X. Zhu et al.
LANCET ONCOLOGY (2019)
Engineering a bispecific antibody with a common light chain: Identification and optimization of an anti-CD3 epsilon and anti-GPC3 bispecific antibody, ERY974
Hirotake Shiraiwa et al.
METHODS (2019)
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Stephen J. Schuster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Role of Glycanation and Convertase Maturation of Soluble Glypican-3 in Inhibiting Proliferation of Hepatocellular Carcinoma Cells
Ahmad Saad et al.
BIOCHEMISTRY (2018)
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Peter R. Galle et al.
JOURNAL OF HEPATOLOGY (2018)
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
Masatoshi Kudo et al.
LANCET (2018)
Overexpression of glypican-3 is a predictor of poor prognosis in hepatocellular carcinoma An updated meta-analysis
Jian Zhang et al.
MEDICINE (2018)
IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor
Keishi Adachi et al.
NATURE BIOTECHNOLOGY (2018)
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
G. K. Abou-Alfa et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Combining expression of GPC3 in tumors and CD16 on NK cells from peripheral blood to identify patients responding to codrituzumab
Gong Chen et al.
Oncotarget (2018)
I-124 codrituzumab imaging and biodistribution in patients with hepatocellular carcinoma
Jorge A. Carrasquillo et al.
EJNMMI RESEARCH (2018)
Anti-glypican-3 monoclonal antibody (codrituzumab/GC33/RO5137382) treatment enhances tumor infiltration of PD-L1-positive macrophages, and combination therapy with anti-PD-L1 monoclonal antibody promotes antitumor effects
Mika Endo et al.
CANCER RESEARCH (2018)
Detecting GPC3-Expressing Hepatocellular Carcinoma with L5 Peptide-Guided Pretargeting Approach: In Vitro and In Vivo MR Imaging Experiments
Weiyue Li et al.
CONTRAST MEDIA & MOLECULAR IMAGING (2018)
A GPC3-specific aptamer-mediated magnetic resonance probe for hepatocellular carcinoma
Menglong Zhao et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2018)
697PA phase I, open-label, multi-center, dose-escalation study of codrituzumab, an anti-glypican-3 monoclonal antibody, in combination with atezolizumab in patients with locally advanced or metastatic hepatocellular carcinoma
A-L Cheng et al.
ANNALS OF ONCOLOGY (2018)
Disruption of PD-1 Enhanced the Anti-tumor Activity of Chimeric Antigen Receptor T Cells Against Hepatocellular Carcinoma
Xingliang Guo et al.
FRONTIERS IN PHARMACOLOGY (2018)
Diagnosis accuracy of serum glypican-3 level in patients with hepatocellular carcinoma: a systematic review with meta-analysis
Jian Li et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS (2018)
Imaging the expression of glypican-3 in hepatocellular carcinoma by PET
Zhen Wang et al.
AMINO ACIDS (2018)
HOXA-AS2 Promotes Proliferation and Induces Epithelial-Mesenchymal Transition via the miR-520c-3p/GPC3 Axis in Hepatocellular Carcinoma
Ying Zhang et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2018)
Perioperative plasma glypican-3 level may enable prediction of the risk of recurrence after surgery in patients with stage I hepatocellular carcinoma
Kazuya Ofuji et al.
ONCOTARGET (2017)
MXR7 facilitates liver cancer metastasis via epithelial-mesenchymal transition
Guishuai Lv et al.
SCIENCE CHINA-LIFE SCIENCES (2017)
An anti-glypican 3/CD3 bispecific T cell-redirecting antibody for treatment of solid tumors
Takahiro Ishiguro et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Long Noncoding RNAs as Biomarkers in Cancer
Luka Bolha et al.
DISEASE MARKERS (2017)
A phase I study of anti-GPC3 chimeric antigen receptor modified T cells (GPC3 CAR-T) in Chinese patients with refractory or relapsed GPC3+hepatocellular carcinoma (r/r GPC3+HCC).
Bo Zhai et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
MicroRNA-133b inhibits hepatocellular carcinoma cell progression by targeting Sirt1
Zhijie Tian et al.
EXPERIMENTAL CELL RESEARCH (2016)
Long noncoding RNA glypican 3 (GPC3) antisense transcript 1 promotes hepatocellular carcinoma progression via epigenetically activating GPC3
Xiao-ting Zhu et al.
FEBS JOURNAL (2016)
Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma
Ghassan K. Abou-Alfa et al.
JOURNAL OF HEPATOLOGY (2016)
Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma
Yukihiro Haruyama et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2016)
Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients
Yu Sawada et al.
ONCOIMMUNOLOGY (2016)
Hepatocellular carcinoma
Josep M. Llovet et al.
NATURE REVIEWS DISEASE PRIMERS (2016)
Circulating Cancer Biomarkers: The Macro-revolution of the Micro-RNA
Francesca Montani et al.
EBIOMEDICINE (2016)
Evaluating clinical and prognostic implications of Glypican 3 in hepatocellular carcinoma.
Sahin Lacin et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Global Cancer Statistics, 2012
Lindsey A. Torre et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2015)
High preoperative levels of serum glypican-3 containing N-terminal subunit are associated with poor prognosis in patients with hepatocellular carcinoma after partial hepatectomy
Yukihiro Haruyama et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Glypican-3 promotes epithelial-mesenchymal transition of hepatocellular carcinoma cells through ERK signaling pathway
Yongle Wu et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2015)
Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial
Andrew X. Zhu et al.
LANCET ONCOLOGY (2015)
Notum deacylates Wnt proteins to suppress signalling activity
Satoshi Kakugawa et al.
NATURE (2015)
Human Monoclonal Antibody Targeting the Heparan Sulfate Chains of Glypican-3 Inhibits HGF-Mediated Migration and Motility of Hepatocellular Carcinoma Cells
Wei Gao et al.
PLOS ONE (2015)
Japanese phase I study of GC33, a humanized antibody against glypican-3 for advanced hepatocellular carcinoma
Masafumi Ikeda et al.
CANCER SCIENCE (2014)
Glypican-3 binds to Frizzled and plays a direct role in the stimulation of canonical Wnt signaling
Mariana Capurro et al.
JOURNAL OF CELL SCIENCE (2014)
First-in-Man Phase I Study of GC33, a Novel Recombinant Humanized Antibody Against Glypican-3, in Patients with Advanced Hepatocellular Carcinoma
Andrew X. Zhu et al.
CLINICAL CANCER RESEARCH (2013)
Glypican-3: a marker and a therapeutic target in hepatocellular carcinoma
Jorge Filmus et al.
FEBS JOURNAL (2013)
Phase I Trial of a Glypican-3-Derived Peptide Vaccine for Advanced Hepatocellular Carcinoma: Immunologic Evidence and Potential for Improving Overall Survival
Yu Sawada et al.
CLINICAL CANCER RESEARCH (2012)
Expression of GPC3 protein and its significance in lung squamous cell carcinoma
Qiang Lin et al.
MEDICAL ONCOLOGY (2012)
The Oncogenic Effect of Sulfatase 2 in Human Hepatocellular Carcinoma Is Mediated in Part by Glypican 3-Dependent Wnt Activation
Jin-Ping Lai et al.
HEPATOLOGY (2010)
Anti-glypican 3 antibodies cause ADCC against human hepatocellular carcinoma cells
Kiyotaka Nakano et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2009)
Glypican 3-expressing gastric carcinoma: Distinct subgroup unifying hepatoid, clear-cell, and α-fetoprotein-producing gastric carcinomas
Tetsuo Ushiku et al.
CANCER SCIENCE (2009)
Glypican-3 expression in clear cell adenocarcinoma of the ovary
Daichi Maeda et al.
MODERN PATHOLOGY (2009)
Mammalian Notum induces the release of glypicans and other GPI-anchored proteins from the cell surface
Alexandra Traister et al.
BIOCHEMICAL JOURNAL (2008)
Anti-Glypican 3 Antibody as a Potential Antitumor Agent for Human Liver Cancer
Takahiro Ishiguro et al.
CANCER RESEARCH (2008)
Glypican-3 inhibits Hedgehog signaling during development by competing with patched for Hedgehog binding
Mariana I. Capurro et al.
DEVELOPMENTAL CELL (2008)
Sulfatase 2 up-regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma
Jin-Ping Lai et al.
HEPATOLOGY (2008)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling
MI Capurro et al.
CANCER RESEARCH (2005)
Usefulness of the novel oncofetal antigen glypican-3 for diagnosis of hepatocellular carcinoma and melanoma
T Nakatsura et al.
BIODRUGS (2005)
PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells
Y Iwai et al.
INTERNATIONAL IMMUNOLOGY (2005)
Methylation analysis of the glypican 3 gene in embryonal tumours
G Boily et al.
BRITISH JOURNAL OF CANCER (2004)
Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma
Y Hippo et al.
CANCER RESEARCH (2004)
Processing by proprotein convertases is required for glypican-3 modulation of cell survival, Wnt signaling, and gastrulation movements
B De Cat et al.
JOURNAL OF CELL BIOLOGY (2003)
Glypican-3: A novel serum and histochemical marker for hepatocellular carcinoma
M Capurro et al.
GASTROENTEROLOGY (2003)
Glypican-3, overexpressed in hepatocellular carcinoma, modulates FGF2 and BMP-7 signaling
Y Midorikawa et al.
INTERNATIONAL JOURNAL OF CANCER (2003)
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
Y Iwai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders
ZW Zhu et al.
GUT (2001)
glypican-3 controls cellular responses to Bmp4 in limb patterning and skeletal development
S Paine-Saunders et al.
DEVELOPMENTAL BIOLOGY (2000)
分享论文
